Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

In patients with alopecia areata, this study found elevated levels of venous thromboembolism markers SFMC and F1 + 2 compared to healthy controls, potentially indicating an increased risk for this condition.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

This systematic review and meta-analysis found that hidradenitis suppurativa is associated with an increased risk of major adverse cardiac events, including cerebrovascular accidents and myocardial infarction, although study heterogeneity affects the magnitude of risk.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This study found that most adverse events reported for HPV vaccines in the VAERS system were non-serious and already known, although less common events suggest the need for further examination.

This review discusses the cardiovascular risks and events associated with anabolic-androgenic steroid use, suggesting the need for further research on some effects.

This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.

This review discusses the effects of hormonal treatments on the physical and mental health of transgender individuals, reporting significant reductions in mental health issues following treatment, but calls for more research on long-term and nonbinary outcomes.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.

This review discusses recent advancements in female contraception and covers topics like adapted regimens, non-invasive sterilization, and the promise of new methods, but it reports no new clinical findings.

This review discusses the timing and management of dyslipidemia screening and intervention in pregnancy and highlights the need for lipid profile assessments each trimester; it reports no clinical results.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This review describes a practical approach for dermatologists to manage adult female acne using hormonal therapies and highlights the importance of identifying possible underlying endocrine disorders like PCOS, but it does not report new findings.

This review discusses the role of androgen therapy and neurosteroids in cerebrovascular health, highlighting the potential risks and benefits and the importance of pharmacogenetic testing, but reports no new experimental results.

This review discusses strategies for managing dermatological symptoms of hyperandrogenism in PCOS by reducing androgen levels and actions, and reports no new clinical results.

This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.

This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.

Higher doses of glucocorticoids increase the risk of blood clots in asthma patients.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This review examines the role of hormones in acne pathogenesis, the use of hormonal therapies for treatment, and the importance of contraceptive counseling during isotretinoin therapy, but reports no new clinical results.

This review discusses the unique challenges faced by transgender patients with end-stage renal disease during the transplant process and outlines current management recommendations, but it reports no new clinical results.

Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.

In this review, the authors examined guidelines and literature on the non-operative treatment of gender dysphoria, highlighting the importance of personalized, multidisciplinary care, and noting that such treatment is generally safe and effective according to WPATH and Endocrine Society recommendations.